R
Ravi Vij
Researcher at Washington University in St. Louis
Publications - 588
Citations - 21929
Ravi Vij is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 59, co-authored 540 publications receiving 18423 citations. Previous affiliations of Ravi Vij include University of Washington & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Initial genome sequencing and analysis of multiple myeloma
Michael A Chapman,Michael S. Lawrence,Jonathan J Keats,Kristian Cibulskis,Carrie Sougnez,Anna C. Schinzel,Christina L. Harview,Jean Philippe Brunet,Gregory J. Ahmann,Mazhar Adli,Mazhar Adli,Kenneth C. Anderson,Kristin G. Ardlie,Daniel Auclair,Angela Baker,P. Leif Bergsagel,Bradley E. Bernstein,Bradley E. Bernstein,Bradley E. Bernstein,Yotam Drier,Yotam Drier,Rafael Fonseca,Stacey Gabriel,Craig C. Hofmeister,Sundar Jagannath,Andrzej Jakubowiak,Amrita Krishnan,Joan Levy,Ted Liefeld,Sagar Lonial,Scott Mahan,Bunmi Mfuko,Stefano Monti,Louise M. Perkins,Robb Onofrio,Trevor J. Pugh,S. Vincent Rajkumar,Alex H. Ramos,David S. Siegel,Andrey Sivachenko,A. Keith Stewart,Suzanne Trudel,Ravi Vij,Douglas Voet,Wendy Winckler,Todd Zimmerman,John D. Carpten,Jeff Trent,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway,Matthew Meyerson,Matthew Meyerson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Gad Getz,Todd R. Golub +58 more
TL;DR: The massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs indicates that cancer genome sequencing of large collections of samples will yield new insights into cancer not anticipated by existing knowledge.
Initial genome sequencing and analysis of multiple myeloma
Michael A Chapman,Michael S. Lawrence,Jonathan J Keats,Kristian Cibulskis,Carrie Sougnez,Anna C. Schinzel,Christina L. Harview,Jean Philippe Brunet,Gregory J. Ahmann,Mazhar Adli,Mazhar Adli,Kenneth C. Anderson,Kristin G. Ardlie,Daniel Auclair,Angela Baker,P. Leif Bergsagel,Bradley E. Bernstein,Bradley E. Bernstein,Bradley E. Bernstein,Yotam Drier,Yotam Drier,Rafael Fonseca,Stacey Gabriel,Craig C. Hofmeister,Sundar Jagannath,Andrzej Jakubowiak,Amrita Krishnan,Joan Levy,Ted Liefeld,Sagar Lonial,Scott Mahan,Bunmi Mfuko,Stefano Monti,Louise M. Perkins,Robb Onofrio,Trevor J. Pugh,S. Vincent Rajkumar,Alex H. Ramos,David S. Siegel,Andrey Sivachenko,A. Keith Stewart,Suzanne Trudel,Ravi Vij,Douglas Voet,Wendy Winckler,Todd Zimmerman,John D. Carpten,Jeff Trent,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway,Matthew Meyerson,Matthew Meyerson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Gad Getz,Todd R. Golub +58 more
TL;DR: In this paper, a massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs was reported, and several new and unexpected oncogenic mechanisms were suggested by the pattern of somatic mutation across the data set.
Journal ArticleDOI
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy,Kouros Owzar,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Paul G. Richardson,Sergio Giralt,Edward A. Stadtmauer,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas G. Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Robert L. Schlossman,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Seiler,Cara A. Rosenbaum,Parameswaran Hari,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Kenneth C. Anderson,Charles A. Linker +39 more
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Journal ArticleDOI
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
John S. Welch,Allegra A. Petti,Christopher A. Miller,Catrina Fronick,Michelle O'Laughlin,Robert S. Fulton,Richard K. Wilson,Jack Baty,Eric J. Duncavage,Bevan Tandon,Yi-Shan Lee,Lukas D. Wartman,Geoffrey L. Uy,Armin Ghobadi,Michael H. Tomasson,Iskra Pusic,Rizwan Romee,Todd A. Fehniger,Keith Stockerl-Goldstein,Ravi Vij,Stephen T. Oh,Camille N. Abboud,Amanda F. Cashen,Mark A. Schroeder,Meagan A. Jacoby,Sharon Heath,Kierstin Luber,Megan Janke,Andrew Hantel,Niloufer Khan,Madina Sukhanova,Randall W. Knoebel,Wendy Stock,Timothy A. Graubert,Matthew J. Walter,Peter Westervelt,Daniel C. Link,John F. DiPersio,Timothy J. Ley +38 more
TL;DR: Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine.
Journal ArticleDOI
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel,Thomas Martin,Michael Wang,Ravi Vij,Andrzej Jakubowiak,Sagar Lonial,Suzanne Trudel,Vishal Kukreti,Nizar J. Bahlis,Melissa Alsina,Asher Chanan-Khan,Francis K. Buadi,Frederic J. Reu,George Somlo,Jeffrey A. Zonder,Kevin W. Song,A. Keith Stewart,Edward A. Stadtmauer,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,Sundar Jagannath +22 more
TL;DR: Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit.